Cyberbiosecurity for biopharmaceutical products
Cybersecurity for biopharmaceutical manufacturing? The "rapid pace of innovation dictates that it is not too early to consider the cyberbiosecurity implications" of the potential dangers that can arise in the industry, argue Mantle et al. in this 2019 paper published in Frontiers in Bioengineering and Biotechnology. From compromised master cell banks to intentional corruption of " the design, reading, and writing of DNA sequences to produce pathogenic, self-replicating entities," the authors demonstrate worst case scenarios and practical considerations that scientists should be considering when incorporating various forms of automation into biopharmaceutical manufacturing. After presenting their scenarios and considerations, they conclude that "current best practices from industrial manufacturing and state-of-the-art cybersecurity could serve as a starting point to safeguard and mitigate against cyberbiosecurity threats to biomanufacturing."